Answers are grounded in this paper and cite their sources.
Background/Objectives National pharmaceutical surveillance can describe medicine availability and relative prices, but it cannot establish household affordability without treatment-cost and purchasing-power data. We assessed recorded availability, national relative prices, and territorial inequality of essential medicines in Peru during 2020–2025.Methods An ecological annual panel integrated 363,183 administrative records; 311,020 were classified as essential medicines. Descriptive analyses, two-way cluster-robust modified Poisson models, and sensitivity analyses addressed repeated observations, missing prices, unspecified care levels, and changes in the product basket.Results Median recorded availability increased from 85.4% in 2020–99.4% in 2025; the proportion below 80% decreased from 47.5% to 36.5%. Excluding unspecified care levels reduced the overall low-availability proportion from 44.9% to 27.4%. Prices were linked for 42.9% of essential-medicine records, and 9.6% of linked records had high relative prices. Low availability and high relative price co-occurred in 4.8% of linked records. Availability Gini declined from 0.082 to 0.037, whereas co-occurrence Gini was 0.262 in 2025 despite a lower mean co-occurrence burden. The East had higher adjusted low-availability prevalence than Center (aPR 1.20; 95% CI 1.08–1.34). Improvement after 2023 persisted in a balanced panel but was attenuated after excluding unspecified care levels.Conclusion Recorded availability improved, with substantial sensitivity to administrative composition. Incomplete and ingredient-level price linkage limits economic interpretation; the findings support targeted surveillance, not conclusions about patient affordability or causal policy effects.
No takes yet. Share an insight, caveat, or question.
Boza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: